10 assets in Histiocytic And Dendritic Cell Neoplasm

Therapeutic assets addressing Histiocytic And Dendritic Cell Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Selpercatinib Histiocytic And Dendritic Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Histiocytic And Dendritic Cell Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Cetuximab Histiocytic And Dendritic Cell Neoplasm	Institut de Recherches Internationales Servier	P1/2	CCC (48)
Panitumumab Histiocytic And Dendritic Cell Neoplasm	Institut de Recherches Internationales Servier	P1/2	CCC (48)
s241656 Histiocytic And Dendritic Cell Neoplasm	Institut de Recherches Internationales Servier	P1/2	CCC (48)
Cyclophosphamide Histiocytic And Dendritic Cell Neoplasm	Mayo Clinic	P1	CC (43)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Histiocytic And Dendritic Cell Neoplasm	Mayo Clinic	P1	CC (43)
Nivolumab Histiocytic And Dendritic Cell Neoplasm	Mayo Clinic	P1	CC (43)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Histiocytic And Dendritic Cell Neoplasm	Mayo Clinic	P1	CC (43)
Ruxolitinib Histiocytic And Dendritic Cell Neoplasm	Mayo Clinic	P1	CC (43)